Rinri Therapeutics
Industrial Biotech
- Membership category
- Corporate
Innovation Centre, 217 Portobello, Sheffield, S1 4DP, United Kingdom
Rinri Therapeutics at a glance
Rinri Therapeutics Ltd is a spin-out from the University of Sheffield, developing a first-in-class cell therapy for hearing loss, the most common sensory deficit in humans. We are targeting sensorineural hearing loss; those patients with damage to specialised cells of the inner ear.
About Rinri Therapeutics
Hearing loss affects everyone, it is the most common sensory disability and affect >90% of those aged over 70. Over 350m people, 5% of the world's population have disabling hearing loss and 90% is caused by damage to specialised sensory cells in the inner ear (sensorineural). There are no approved pharmaceutical treatments, medical interventions are limited to palliative devices - hearing aids and cochlear implants - which offer poor outcomes for patients. Our approach is to return the cochlear to function and restore hearing by replacing the cells that have been lost or damaged through an exogenous stem cell therapy.
